Hepatocellular carcinoma in patients listed for liver transplantation

Current and future allocation policy and management strategies for the individual patient

Joel P. Wedd, Eric Nordstrom, Trevor Nydam, Janette Durham, Michael Zimmerman, Thor Johnson, W. Thomas Purcell, Scott W. Biggins

Research output: Contribution to journalArticle

Abstract

Liver transplantation can provide definitive cure for patients with cirrhosis and hepatocellular carcinoma (HCC) when used appropriately. Advances in the management of HCC have allowed improved control of HCC while waiting for liver transplantation and new approaches to candidate selection particularly with regard to tumor burden and downstaging protocols. Additionally, there have been recent changes in allocation policy related to HCC in the U.S. that cap the HCC MELD exception at 34 points and implement a 6-month delay in a HCC MELD exception. This review examines the U.S. liver transplant allocation policy related to HCC, comprehensively details locoregional therapy options in HCC patients awaiting liver transplantation, and considers the impact of an increasing burden of HCC on future liver graft allocation policy. Liver Transpl 21:1543-1552, 2015.

Original languageEnglish (US)
Pages (from-to)1543-1552
Number of pages10
JournalLiver Transplantation
Volume21
Issue number12
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Fingerprint

Liver Transplantation
Hepatocellular Carcinoma
Liver
Transplants
Tumor Burden
Fibrosis

ASJC Scopus subject areas

  • Surgery
  • Transplantation
  • Hepatology

Cite this

Hepatocellular carcinoma in patients listed for liver transplantation : Current and future allocation policy and management strategies for the individual patient. / Wedd, Joel P.; Nordstrom, Eric; Nydam, Trevor; Durham, Janette; Zimmerman, Michael; Johnson, Thor; Thomas Purcell, W.; Biggins, Scott W.

In: Liver Transplantation, Vol. 21, No. 12, 01.12.2015, p. 1543-1552.

Research output: Contribution to journalArticle

Wedd, JP, Nordstrom, E, Nydam, T, Durham, J, Zimmerman, M, Johnson, T, Thomas Purcell, W & Biggins, SW 2015, 'Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient', Liver Transplantation, vol. 21, no. 12, pp. 1543-1552. https://doi.org/10.1002/lt.24356
Wedd, Joel P. ; Nordstrom, Eric ; Nydam, Trevor ; Durham, Janette ; Zimmerman, Michael ; Johnson, Thor ; Thomas Purcell, W. ; Biggins, Scott W. / Hepatocellular carcinoma in patients listed for liver transplantation : Current and future allocation policy and management strategies for the individual patient. In: Liver Transplantation. 2015 ; Vol. 21, No. 12. pp. 1543-1552.
@article{ebdd09c887c1438e903f5bb1cef49fdd,
title = "Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient",
abstract = "Liver transplantation can provide definitive cure for patients with cirrhosis and hepatocellular carcinoma (HCC) when used appropriately. Advances in the management of HCC have allowed improved control of HCC while waiting for liver transplantation and new approaches to candidate selection particularly with regard to tumor burden and downstaging protocols. Additionally, there have been recent changes in allocation policy related to HCC in the U.S. that cap the HCC MELD exception at 34 points and implement a 6-month delay in a HCC MELD exception. This review examines the U.S. liver transplant allocation policy related to HCC, comprehensively details locoregional therapy options in HCC patients awaiting liver transplantation, and considers the impact of an increasing burden of HCC on future liver graft allocation policy. Liver Transpl 21:1543-1552, 2015.",
author = "Wedd, {Joel P.} and Eric Nordstrom and Trevor Nydam and Janette Durham and Michael Zimmerman and Thor Johnson and {Thomas Purcell}, W. and Biggins, {Scott W.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1002/lt.24356",
language = "English (US)",
volume = "21",
pages = "1543--1552",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Hepatocellular carcinoma in patients listed for liver transplantation

T2 - Current and future allocation policy and management strategies for the individual patient

AU - Wedd, Joel P.

AU - Nordstrom, Eric

AU - Nydam, Trevor

AU - Durham, Janette

AU - Zimmerman, Michael

AU - Johnson, Thor

AU - Thomas Purcell, W.

AU - Biggins, Scott W.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Liver transplantation can provide definitive cure for patients with cirrhosis and hepatocellular carcinoma (HCC) when used appropriately. Advances in the management of HCC have allowed improved control of HCC while waiting for liver transplantation and new approaches to candidate selection particularly with regard to tumor burden and downstaging protocols. Additionally, there have been recent changes in allocation policy related to HCC in the U.S. that cap the HCC MELD exception at 34 points and implement a 6-month delay in a HCC MELD exception. This review examines the U.S. liver transplant allocation policy related to HCC, comprehensively details locoregional therapy options in HCC patients awaiting liver transplantation, and considers the impact of an increasing burden of HCC on future liver graft allocation policy. Liver Transpl 21:1543-1552, 2015.

AB - Liver transplantation can provide definitive cure for patients with cirrhosis and hepatocellular carcinoma (HCC) when used appropriately. Advances in the management of HCC have allowed improved control of HCC while waiting for liver transplantation and new approaches to candidate selection particularly with regard to tumor burden and downstaging protocols. Additionally, there have been recent changes in allocation policy related to HCC in the U.S. that cap the HCC MELD exception at 34 points and implement a 6-month delay in a HCC MELD exception. This review examines the U.S. liver transplant allocation policy related to HCC, comprehensively details locoregional therapy options in HCC patients awaiting liver transplantation, and considers the impact of an increasing burden of HCC on future liver graft allocation policy. Liver Transpl 21:1543-1552, 2015.

UR - http://www.scopus.com/inward/record.url?scp=84977636383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977636383&partnerID=8YFLogxK

U2 - 10.1002/lt.24356

DO - 10.1002/lt.24356

M3 - Article

VL - 21

SP - 1543

EP - 1552

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 12

ER -